Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer. FE [Internet]. 2006 Sep. 15 [cited 2025 Oct. 29];7(2):97-117. Available from: https://journals.seedstm.com/index.php/FE/article/view/680